000 01240 a2200325 4500
005 20250516052748.0
264 0 _c20120124
008 201201s 0 0 eng d
022 _a1759-5037
024 7 _a10.1038/nrendo.2011.141
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aGild, Matti L
245 0 0 _aMultikinase inhibitors: a new option for the treatment of thyroid cancer.
_h[electronic resource]
260 _bNature reviews. Endocrinology
_cAug 2011
300 _a617-24 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aClinical Trials as Topic
650 0 4 _aClinical Trials, Phase III as Topic
650 0 4 _aHumans
650 0 4 _aMitogen-Activated Protein Kinases
_xantagonists & inhibitors
650 0 4 _aPhosphatidylinositol 3-Kinases
_xmetabolism
650 0 4 _aPhosphoinositide-3 Kinase Inhibitors
650 0 4 _aProtein Kinase Inhibitors
_xpharmacology
650 0 4 _aThyroid Neoplasms
_xdrug therapy
700 1 _aBullock, Martyn
700 1 _aRobinson, Bruce G
700 1 _aClifton-Bligh, Roderick
773 0 _tNature reviews. Endocrinology
_gvol. 7
_gno. 10
_gp. 617-24
856 4 0 _uhttps://doi.org/10.1038/nrendo.2011.141
_zAvailable from publisher's website
999 _c21105944
_d21105944